← Back to patent-cliff list
EA-230
Tier C — Watch / tradeEA-230
Exponential Biotherapies Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Renal impairment, Coronary artery lesion, 全身炎症反应综合征, 内毒素血症
Regional status
US
Phase III
2026-08-01
EU
Phase III
2026-08-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of EA-230?
Approved indications include: Renal impairment, Coronary artery lesion, 全身炎症反应综合征, 内毒素血症.
When does the EA-230 patent expire?
No public expiry year is available for EA-230 yet; this page updates once verified.
How do I get a quote for EA-230 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29